LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors

Journal of Immunotherapy

Volumn 26, Issue 4, 2003, Pages 320-331

  Li, Jiali ^a   Hu, Peisheng ^a   Khawli, Leslie A ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chemokines; Chemotaxis; Fusion proteins; Immunohistochemistry; Immunotherapy; Tumor necrosis therapy

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; PROTEIN A;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN RETRIEVAL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CHEMOTAXIS; CHROMOSOME 17Q; CONTROLLED STUDY; DENDRITIC CELL; DNA BINDING; DNA TRANSFECTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG UPTAKE; EXPRESSION VECTOR; FEMALE; GENE CLUSTER; GENE INSERTION; GENE LINKAGE GROUP; GENE LOCATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; LYMPHOCYTIC INFILTRATION; MOUSE; MYELOMA CELL; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEQUENCE TAGGED SITE; SOLID TUMOR; T LYMPHOCYTE SUBPOPULATION; TARGET CELL DESTRUCTION; TISSUE SECTION; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, CD11B; ANTIGENS, CD11C; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SEPARATION; CHEMOKINES, CC; CHEMOTAXIS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GLUTAMATE-AMMONIA LIGASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MULTIGENE FAMILY; NECROSIS; NEOPLASMS, EXPERIMENTAL; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0037829431     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200307000-00004     Document Type: Article

References (40)

1. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol. 2001;2:95-101.
2. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001;2:108-115.
3. Vaddi K, Keller M, Newton RC. The Chemokine facts book. 1997, Academic Press Harcourt Brace & Company, Publishers, San Diego, CA, pp. 10-17.
4. Miyagishi R, Kikuchi S, Fukazawa T, et al. Macrophage inflammatory protein-1 in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurosci. 1995;129:223-227.
5. Baroudy BM. A Small molecule antagonist of CCR5 that effectively inhibits HIV-1 potential as a novel antiretroviral agent. 7th Conference on Retroviruses and Opportunistic Infections. 2000.
6. Homey B, Muller A, Zlotnik A. Chemokines: Agents for the immunotherapy of cancer? Nature Reviews Immunology. 2002;2:175-184.
7. Naruse K, Ueno M, Satoh T, et al. A YAC contig of the human CC chemokine genes clustered on chromosome 17q11.2. Genomics. 1996;34:236-240.
8. Howard OMZ, Dong HF, Shirakawa A-K, et al. LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood. 2000;96:840-845.
9. Giovarelli M, Cappello P, Forni G, et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with and impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol. 2000;164:3200-3206.
10. Hornick J, Khawli L, Hu P, et al. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res. 1999;5:51-60.
11. Hornick JL, Khawli LA, Hu P, et al. Chimeric CLL-1 antibody fusion proteins containing granulocyte macrophage colony-stimulating factor or interleukin-1 with specificity for B-Cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood. 1997;89:4437-4447.
12. Hu P, Hornick JL, Glasky MS, et al. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res. 1996;56:4998-5004.
13. Sharifi J, Khawli LA, Li J, et al. Generation of human interferon gamma and tumor necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics (in press).
14. Chen F-M, Hansen EB, Taylor CR, et al. Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids. J Natl Cancer Inst. 1991;83:200-204.
15. Gillies SD, Lan Y, Wesolowski JS, et al. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol. 1998;160:6195-6203.
16. Challita-Eid P, Abboud C, Morrison S, et al. A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol. 1999;161:3729-3736.
17. Hornick JL, Hu P, Khawli LA, et al. chTNT-3/B, a new chemically modified chimeric monoclonal antibody directed against DNA for the tumor necrosis treatment of solid tumors. Cancer Biother Radiopharm. 1998;13:255-268.
18. Hedrick JA, Helms A, Vicari A, et al. Characterization of a novel chemokine, HCC-4, whose expression is increased by interleukin-10. Blood. 1998;91:4242-4247.
19. Epstein AL, Chen D, Ansari A, et al. Radioimmunodetection of necrotic lesions in human tumors using I-131 labeled TNT-1 F(ab′)2 monoclonal antibody. Antibody Immunoconjugates Radiopharmaceuticals. 1991;4:151-161.
20. Frankel ME, Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radiommunoassay: an analysis of the interaction between hybridoma proteins and influenza virus. Mol Immunol. 1979;16:101-106.
21. Zuckier LS, Georgescu L, Chang CJ, et al. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer. 1994;73:794-799.
22. Gillies S, Reilly E. LO K-M, Reisfeld RA. Antibody-targeted interleukin-2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA. 1992;89:1428-1432.
23. Penichet ML, Harvill ET, Morrison SL. Antibody-IL-2 fusion proteins: a novel strategy for immune protection. Hum Antibodies. 1997;8:106-118.
24. Penichet ML, Dela Cruz JS, Shin SU, et al. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies. 2001;10:43-49.
25. Christ O, Matzku S, Burger C, et al. Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo. Clin Cancer Res. 2001;7:1385-1397.
26. Batova A, Kamps A, Gillies SD, et al. The Ch14, 18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res. 1999;5:4259-4263.
27. Peng LS, Penichet ML, Morrison SL. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol. 1999;163:250-258.
28. Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996;7:1545-1553.
29. Braun SE, Chen K, Foster RG, et al. The CC chemokine CK beta-1 1/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol. 2000;164:4025-4031.
30. Yao L, Pike SE, Pittaluga SP, et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother. 2002;51:358-366.
31. Arenberg D, Zlotnick A, Strom S, et al. The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother. 2001;49:587-592.
32. Biragyn A, Tani K, Grimm MC, et al. Genetic fusion of chemokines to a self tumor antigen induced protective, T-cell dependent antitumor immunity. Nat Biotechnol. 1999;17:253-259.
33. Rollins BJ. Chemokines and cancer. 1999, Humana Press, Totowa, NJ, pp. 35-49.
34. Carlos TM. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukocyte Biol. 2001;70:171-184.
35. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukocyte Biol. 2000;68:1-8.
36. Baggiolini M, Dewald B, Moser B. Human Chemokines: an update. Ann Rev Immunol. 1997;15:675-705.
37. Arenberg DA, Kunkel SL, Polverini PJ, et al. Interferon - inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 1996;184:981.
38. Emtage P, Wan Y, Hitt M, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther. 1999;10:697-709.
39. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996;2:1090-1095.
40. Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol. 2000;164:3112-3122.